CSPG4 (chondroitin sulfate proteoglycan 4), also known as human integral melanoma-associated chondroitin sulfate proteoglycan (MCSP) or neuron-glial antigen 2 (NG2), is originally identified on the surface of cutaneous melanoma cells for its namesake. Normally, it is extensively expressed in glial cells, immature cell phenotypes (precursor/progenitor cells, including putative stem/progenitor cells of both epithelial and mesodermal origin), brain, gastrointestinal tract, endocrine organs of the adult human body, and functions to promote endothelial cell motility, angiogenesis, adhesion, cell-substratum interactions and cell-cell contacts. As a unique multivalent transmembrane proteoglycan, CSPG4 is accountable for many of the interactions taking place between cancer cells and their microenvironment, it also promotes the myriad of cellular events propagating tumor growth and spreading via accumulation in the advancing cytoplasmic front, in filopodial extensions and at cell-substratum contact areas. Particularly, CSPG4 is selectively expressed on 90 % of human malignant melanoma cells to stabilize cell-substratum interactions. Since CSPG4 is widely recognized as a prognostic factor, a valuable tool for ex vivo and non-invasive molecular diagnostics by virtue of its tight association with malignancy, it is envisioned as a tantalizing therapeutic target for anti-CSPG4 CAR-T cell therapy.
Schematic regulation of tumor growth and spreading by NG2/CSPG4
Theranostic Journal (2015)
Anti-CSPG4 CAR-T Cell Therapy
Although CSPG4 is envisioned as a tantalizing therapeutic target for anti-CSPG4 CAR-T cell therapy, the pre-clinical and clinical studies are rarely reported. Creative Biolabs helps researchers capture the brighter and prosperous future of anti-CSPG4 CAR-T cell therapy and make the very first scientific history.
Animal Models for in vivo Study of anti-CSPG4 CAR-T Cell Therapy
Creative Biolabs possesses almost the whole categories of mouse models for melanoma studies, including cell line xenografts (originated from cell lines: B16, 1205 Lu, 451 Lu, etc.), patient-derived tumor xenografts (PDTXs, originated from WM164, WM793B or any other customized patient-derived tumor cells), syngeneic models (originated from Harding-Passey cell, Cloudman S91 cell, B16, etc.) and genetically engineered mouse models (GEMMs, including CDKN2A, RAS, PTEN/BRAF, RCAS/TVA, RET, GRM1, GNAQ, etc.). Particularly, Creative Biolabs can use the newest strategy to generate xenografts with primary melanoma cells tittered down to single cell in NOD/SCID IL-2 receptor gamma chain knockout (NSG) mice. Beyond above, Creative Biolabs also provides UVR-induced models and chemically (DMBA, TPA) induced mouse models. Since each model only reveals limited insights into melanoma behavior, Creative Biolabs helps researchers optimize the best model combination to perfect experiment design and improve scientific understanding of coming results.
In vivo Assay Parameters and Techniques
At Creative Biolabs, we offer the most exquisite and comprehensive service platform for preclinical anti-CSPG4 CAT-T cell therapy research.
Tumor remission monitored by tumor volume recording or bioluminescence imaging and survival curve tracking
Viability and Bio-distribution Studies
Durability, GLP-compliant bio-distribution studies
Pilot tolerability (MTD, The route of administration, Dose regimen/response/onset)
Clinical observation (body weight, feed consumption, ophthalmologic and clinical pathology)
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
Complete necropsy, organ weight
You request, Creative Biolabs offers the best.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE